Efficacy and safety of acetylcysteine for the prevention of liver injury in COVID-19 intensive care unit patients under treatment with remdesivir Prevention of liver injury in severe Covid-19 pneumonia
Gastroenterology and Hepatology from Bed to Bench,
Aim: The present double-blinded placebo-controlled randomized clinical trial evaluated prophylactic use of acetylcysteine for the prevention of liver injury in patients with severe COVID-19 pneumonia under treatment with remdesivir.
Background: Liver injury is reportedly common in patients with severe COVID-19 pneumonia and can occur not only as a result of disease progression, but as an iatrogenic reaction to remdesivir.
Methods: A total of 83 adult patients with severe COVID-19 pneumonia were randomly assigned in parallel groups to receive either acetylcysteine or placebo. All the patients received standard care according to institutional protocols, including remdesivir for a total of five days. One gram acetylcysteine was administered intravenously every 12 hours for 42 patients, and 41 patients received the same volume of 0.9% sodium chloride as placebo (Trial Registration: www.irct.ir identifier, IRCT20210726051995N1).
Results: After 5 days, median aspartate transaminase (AST) and alanine transaminase (ALT) levels were significantly lower in the acetylcysteine than in the placebo group. Of those who received the placebo, 30 (73.2%), 4 (9.7%), and 3 (7.3%) patients had serum AST levels elevated between 1-2.5, 2.5-5, and over 5 times the upper limit of normal (ULN), respectively; while in the acetylcysteine group, 33 (78.6%) and 0 patients had AST levels between 1-2.5 and over 2.5 times ULN, respectively (p-value=0.037). In the acetylcysteine group, 23 (54.8%), 1 (2.4%), and 1 (2.4%) patient had serum ALT levels elevated between 1-2.5, 2.5-5, and over 5 times ULN, respectively; in the placebo group, however, 24 (58.5%), 7 (17.1%), and 1 (2.4%) patient had serum ALT levels between 1-2.5, 2.5-5, and over 5 times ULN, respectively (p-value=0.073).
Conclusion: Intravenous administration of acetylcysteine significantly prevents liver transaminases elevation and liver injury in seriously ill COVID-19 patients treated with remdesivir.
- liver injury
- clinical trial
How to Cite
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054-62.
Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: An A–Z literature review. Dig Liver Dis 2021;53:146.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052-9.
Ridruejo E, Soza A. The liver in times of COVID-19: What hepatologists should know. Ann Hepatol 2020;19:353-358.
Gurala D, Al Moussawi H, Philipose J, Abergel JR. Acute liver failure in a COVID-19 patient without any preexisting liver disease. Cureus 2020;12:e10045.
Zampino R, Mele F, Florio LL, Bertolino L, Andini R, Galdo M, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int 2020;14:881-3.
Carothers C, Birrer K, Vo M. Acetylcysteine for the treatment of suspected remdesivir‐associated acute liver failure in COVID‐19: A case series. Pharmacotherapy 2020;40:1166-71.
Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. Remdesivir for treatment of COVID-19; An updated systematic review and meta-analysis. Eur J Pharmacol 2021:173926.
Madsen LW. Remdesivir for the Treatment of Covid-19-Final Report. N Engl J Med 2020;338:1813-26.
Montastruc F, Thuriot S, Durrieu G. Hepatic disorders with the use of remdesivir for coronavirus 2019. Clin Gastroenterol Hepatol 2020;18:2835-6.
Lescure F-X, Bouadma L, Nguyen D, Parisey M, Wicky P-H, Behillil S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: A case series. Lancet Infect Dis 2020;20:697-706.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020;382:2327-36.
Leegwater E, Strik A, Wilms EB, Bosma LB, Burger DM, Ottens TH, et al. Drug-induced liver injury in a patient with coronavirus disease 2019: Potential interaction of remdesivir with P-Glycoprotein inhibitors. Clin Infect Dis 2021;72:1256-8.
Makarem J, Naghibi N, Beigmohammadi MT, Foroumandi M, Mehrpooya M. A case report of progressive liver failure inappropriate to decompensated heart failure following infection with COVID-19. Cureus 2020;12:e10142.
Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137:856-64.
Will JS, Snyder CJ, Westerfield KL. N-Acetylcysteine (NAC) for the prevention of liver failure in heat injury-mediated ischemic hepatitis. Mil Med 2019;184:565-7.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-78.
Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infec Dis 2020;20:425-34.
Bloom PP, Meyerowitz EA, Reinus Z, Daidone M, Gustafson J, Kim AY, et al. Liver biochemistries in hospitalized patients with COVID‐19. Hepatology 2021;73:890-900.
Spinner CD, Gottlieb RL, Criner GJ, López JRA, Cattelan AM, Viladomiu AS, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 2020;324:1048-57.
Xu R, Tao A, Bai Y, Deng Y, Chen G. Effectiveness of N‐acetylcysteine for the prevention of contrast‐induced nephropathy: a systematic review and meta‐analysis of randomized controlled trials. J Am Heart Assoc 2016;5:003968.
Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med Hypotheses 2020;143:109862.
Liu Y, Wang M, Luo G, Qian X, Wu C, Zhang Y, et al. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: A case report. Medicine (Baltimore) 2020;99:e22577.
Farooqi FI, Morgan RC, Dhawan N, Dinh J, Yatzkan G, Michel G. Airway hygiene in COVID-19 pneumonia: treatment responses of 3 critically ill cruise ship employees. Am J Case Rep 2020;21:926596-1.
de Alencar JCG, Moreira CdL, Müller AD, Chaves CE, Fukuhara MA, da Silva EA, et al. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by Coronavirus Disease 2019 (COVID-19). Clin Infect Dis 2021;72:736-41.
Avdeev SN, Gaynitdinova VV, Merzhoeva ZM, Berikkhanov ZG-M. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. J Infect 2022;84:94-118.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times